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Carbon monoxide (CO) is an odorless, tasteless and colorless gas which is generated
by heme oxygenase enzymes (HOs). HOs degrade heme releasing equimolar amounts
of CO, iron and biliverdin, which is subsequently reduced to bilirubin. CO shares
many properties with nitric oxide (NO), an established cellular messenger. Both CO
and NO are involved in neural transmission and modulation of blood vessel function,
including their relaxation and inhibition of platelet aggregation. CO, like NO, binds to
heme proteins, although CO binds only ferrous (FeII) heme, whereas NO binds both
ferrous and ferric (FeIII). CO enhances the activity of guanylate cyclase although it is
less potent than NO. In contrast, CO inhibits other heme proteins, such as catalase or
cytochrome P450. The effects of CO on gene expression can be thus varied, depending
on the cellular microenvironment and the metabolic pathway being influenced. In this
review the regulation of gene expression by HO/CO in the cardiovascular system is
discussed. Recent data, derived also from our studies, indicate that HO/CO are signifi-
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cant modulators of inflammatory reactions, influencing the underlying processes
such as cell proliferation and production of cytokines and growth factors.
Carbon monoxide has been known since
17th century as a poisonous gas (“the silent
killer”). In 1857 Claude Bernard determined
that the gas produces asphyxia by reversibly
combining with hemoglobin (Piantadosi,
2002). Innumerable deaths have resulted
from CO created by incomplete combustion of
organic materials. Recently its concentration
in the atmosphere, being a result of technolog-
ical processes and fumes produced by our
cars, is monitored and alerts our conscious-
ness when reported to be too high in the
smoggy air of our cities. Additionally, CO is a
component of cigarette smoke. Due to such a
bad reputation not many people, including sci-
entists, are willing to consider its significance
as a player of physiological, not only patholog-
ical processes in our organism.
Formation of CO in the body was demon-
strated in 1952 by Sjöstrand, who reported
that decomposition of hemoglobin in vivo led
to CO production (Sjöstrand, 1952). In 1968
heme oxygenase, the enzymatic source of CO
was identified by Tenhunen et al. (1968; 1969;
1970), and in the mid 80’s two isoforms of the
HO enzyme were discovered and cloned
(Rotenberg & Maines, 1990; Shibahara et al.,
1985; Yoshida et al., 1988). Heme oxygenase-1
(HO-1), an inducible isoform and HO-2, a con-
stitutive form cleave and oxidize the
-methene bridge of the heme molecule yield-
ing equimolar amounts of biliverdin, CO and
iron (for a review see: Maines, 1997) (Fig. 1).
The catalytic activity of HO requires a con-
certed action of microsomal NADPH-cyto-
chrome P450 reductase to transfer electrons
to the HO-heme complex.
In the last few years evidence has accumu-
lated showing that the HO enzymes and their
by-products are important players in the cellu-
lar metabolism. This review is intended to dis-
cuss some of those data demonstrating the
significance of CO in modulation of cellular in-
flammatory reaction.
HEME OXYGENASES AND THEIR
ENZYMATIC ACTIVITY
Currently three isoforms of HO are known:
HO-1, HO-2 and HO-3. HO-1 (termed also
hsp32) is a stress inducible enzyme which can
be expressed most probably in every cell fac-
ing contact with noxious stimuli (for a review
see: Maines, 1997). Hence, HO-1 induction
can be regarded as a general response to oxi-
dant stress (Applegate et al., 1991). HO-1 can
represent a secondary protective system,
while the primary defense mechanism against
oxidative stress is glutathione (Meister,
1994). Interestingly, glutathione depletion re-
sults in a strong induction of HO-1 (Applegate
et al., 1991; Lautier et al., 1992; Ewing &
Maines, 1993) supporting the importance of
HO-1 in cellular protective mechanisms.
HO-2 is a constitutive gene, expressed in
neurons, endothelium and many other cell
types. The only known inducers of HO-2 activ-
ity are adrenal glucocorticoids (Weber et al.,
1994) but it is also possible that activation of
protein kinase C can result in an increased
degradation of heme by the HO-2 isoform
(Baranano & Snyder, 2001). HO-2 is involved
in the regulation of neural system function-
ing, modulating the neural transmission in
central nervous system, digestive system and
in male copulatory organ (for a review see:
Maines, 1997; Baranano & Snyder, 2001;
Snyder & Baranano, 2001).
HO-3 is a newly identified isoform (McCoub-
rey et al., 1997) and has been found only in
rats (Scapagnini et al., 2002). It is constitu-
tively expressed in the liver, spleen, brain and
kidney, but its ability to degrade heme is
much limited in comparison with HO-1 and
HO-2 (McCoubrey et al., 1997). The HO-3 gene
does not contain introns which suggests that
HO-3 could have arisen by retrotransposition
of the HO-2 gene (Scapagnini et al., 2002).
HO-3 is believed to function as a heme sensing
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or heme binding protein rather than a
heme-degrading enzyme (McCoubrey et al.,
1997), but its biological role requires further
elucidation.
The activity of HO-1 generates colour effects.
When large amounts of heme are released
from destroyed erythrocytes due to a physical
insult on blood vessels in the skin and mus-
cles, HO-1, induced by heme, starts its degra-
dation. The black heme is transformed to
green biliverdin, and when the bruise is
dissapearing, the yellowish bilirubin appears.
Basing on the biochemical activities of HO,
its products have for a long time been recog-
nized only as the waste of heme cleavage. Ad-
ditionally, when heme degradation occurs un-
der pathological conditions, significant health
disturbances may arise. Hence, it has been
customary to regard HO as an enzyme, the ac-
tivity of which results in the clinical problem
of hyperbilirubinemia leading to jaundice.
However, ample evidence has recently accu-
mulated indicating that HO activity and all its
by-products play important physiological
roles (for reviews see: Choi & Otterbein, 2002;
Foresti & Motterlini, 1999; Hill-Kapturczak et
al., 2002; Maines, 1997; Otterbein & Choi,
2000) (Fig. 1).
First, HO activity removes the prooxidant
heme (Balla et al., 1991; Jeney et al., 2002;
Quan et al., 2002; Vercellotti et al., 1994). Sec-
ond, both biliverdin and bilirubin have antioxi-
dant properties, efficiently scavenging reactive
oxygen species and inhibiting lipid pero-
xidation (Baranano et al., 2002; Stocker et al.,
1987a; 1987b). Third, iron released from heme
enhances the synthesis of ferritin, which addi-
tionally has antioxidant capabilities (Balla et
al., 1992). Fourth, HOs, or at least HO-1, pre-
vent free iron accumulation in the cells not
only indirectly by stimulating ferritin produc-
tion, by also directly by extruding iron oustide
the cell (Ferris et al., 1999). In this activity
HO-1 cooperates with a recently identified
Fe-ATP pump (Baranano et al., 2000). An indi-
cation for a role of HO-1 in iron extrusion is the
accumulation of iron in the cells of HO-1 knock-
out mice (Poss & Tonegawa, 1997b; 1997c) or
in the liver and kidney of a boy who lacked a
functional HO-1 gene (Yachie et al., 1999). Ac-
cordingly, gene transfer of HO-1 to cells de-
rived from HO-1 knockout animals restored
the cells’ capability to control the cellular iron
level (Ferris et al., 1999).
Finally, CO, the “notoriously infamous”
by-product of HO activity enters recently the
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Figure 1. Mech-
anisms of heme
oxygenase activ-
ity
scene as an important modulator of many
physiological processes. Particularly, it plays
a role in neural transmission, is necessary for
ejaculation, involved in the homeostatic con-
trol of cardiovascular function and appears to
modulate gene expression in many cell types
(for reviews see: Foresti & Motterlini, 1999;
Snyder & Baranano, 2001). However, due to
space limitations we will discuss here only the
recently investigated activities of CO in the
pathways governing the synthesis of inflam-
matory cytokines and growth factors.
CO PRODUCTION AND MECHANISMS
OF CO EFFECTS ON CELLULAR
FUNCTION
HOs are the main producers of CO in the hu-
man body. Much smaller amounts of CO can
also derive from other sources, like lipid
peroxidation (Fig. 2) (for a review see: Pian-
tadosi, 2002). CO is formed at the rate of 16.4
mol/h in the human body and the daily pro-
duction of CO is substantial, reaching more
than 12 ml (500 mole). However, average
physiological concentrations of CO in tissues
are rather in the low nanomolar range (for a
review see: Piantadosi, 2002). On the other
hand, increased production of CO has been
demonstrated in chronic inflammatory lung
diseases, such as obstructive pulmonary dis-
ease, cystic fibrosis, and asthma as well as in
infectious pulmonary diseases (Kharitonov &
Barnes, 2002).
The action of CO depends primarily on its
ability to bind heme proteins and to inhibit or
alter their biochemical functions (for a review
see: Piantadosi, 2002). By interacting with
heme proteins CO differentially influences
electron-transport reactions producing either
prooxidant or antioxidant effects. The action
of CO is dependent on its concentration, the
concentration of O2 as well as on the availabil-
ity of reduced transition metals, such as iron
or copper (cited after: Piantadosi, 2002).
Some activities of CO resembles those of NO
(for reviews see: Baranano & Snyder, 2001;
Snyder et al., 1998). CO, like NO, avidly binds
heme proteins with iron in the reduced fer-
rous state ([Fe(II)], but unlike NO, does not
bind ferric iron [Fe(III)]. Like NO, CO acti-
vates soluble guanylate cyclase (Brune et al.,
1990; Furchgott & Jothianandan, 1991;
Karlsson et al., 1985; Utz & Ullrich, 1991),
leading to a several-fold increase in the pro-
duction of cGMP, although its potency in stim-
ulation of this effect is about 30–100 times
lower than that of NO (Kharitonov et al.,
1995). Therefore, due to such a weak influ-
ence of CO on guanylate cyclase, the physio-
logical significance of this activation is in
doubt. It is, however, suggested that the effect
of CO on guanylate cyclase can be potentiated
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Figure 2. The
sources of car-
bon monoxide
(based on data
from Vreman et
al., 2002)
by some as yet unknown co-stimulators. The
rationale for such a hypothesis was a discov-
ery of YC-1, a benzyloid derivative, which aug-
ments CO-mediated induction of cGMP pro-
duction to a level attained by NO (Friebe &
Koesling, 1998; Friebe et al., 1996).
Additionally, it is possible that CO may am-
plify the NO-mediated activation of guanylate
cyclase (Ingi et al., 1996; Cao et al., 2000). CO
may also exert its activity through a direct in-
fluence on NO. Indeed, low concentrations of
CO stimulate NO release and augment the
production of the strong oxidant peroxynitite
in vascular cells (Thom et al., 1999; 2000).
Other heme proteins, such as myoglobin,
cytochrome c oxidase, cytochrome P450,
catalase and tryptophan dioxygenase can be
also influenced by CO (for a review see:
Piantadosi, 2002). In contrast to guanylate
cyclase, however, CO inhibits their catalytic
activities. As a result, a significant cellular ox-
idative stress can be produced by CO in vascu-
lar endothelium (Thom et al., 1999; 2000) and
in other cell types in vivo (Piantadosi, 2002).
This occurs already after low-level CO expo-
sure (100 p.p.m.) and can generate a signifi-
cant lipid peroxidation. Such an effect can be
blocked by superoxide dismutase and iron
chelators (Piantadosi, 2002).
CO can influence gene expression in several
ways. First, an increase in CO concentration
in vivo will result in carboxyhemoglobin for-
mation and decreased oxygenation and
hypoxia. Hypoxia is a physiological regulator
of important biological processes, including
erythropoiesis, angiogenesis, glycolysis and
tissue remodeling (for a review see: Kourem-
banas, 2002). It may originate from a de-
crease in O2 concentration, but can also occur
when blood hemoglobin is blocked by CO.
Second, local effects of CO may derive from
its interaction with NO (for a review see:
Hartsfield, 2002). CO can cause a release of
NO from its heme-bound intracellular pool,
which may result not only in activation of
guanylate cyclase, but also in nitrosylation of
protein thiol groups (Thorup et al., 1999;
Foresti et al., 1999; Marshall et al., 2000).
Through those ways NO can influence gene ex-
pression (for reviews see: Dulak & Józkowicz,
2003; Marshall et al., 2000). Such effects can
occur either in cells constitutively generating
NO, like neurons and endothelial cells, or in
cells producing significant amounts of NO by
the action of inducible nitric oxide synthase
(iNOS). A combination of high concentrations
of NO and CO can influence mitochondrial
cytochromes, causing their inhibition and for-
mation of reactive oxygen species (ROS) lead-
ing to lipid peroxidation (Agarwal et al., 1995;
Koehler & Traystman, 2002). ROS induced by
CO can influence the activity of several tran-
scription factors and kinases, as has been
demonstrated so far for NF-B and p38 kinase
(Brouard et al., 2002) (see below).
Third, the cellular effect of CO can be inde-
pendent of hypoxia and interaction with NO.
As mentioned, CO can induce the generation
of hydrogen peroxide, maybe through induc-
tion of the expression of manganese super-
oxide dismutase (MnSOD) (Frankel et al.,
2000) or by inhibition of catalase activity
(Zhang & Piantadosi, 1992; Piantadosi, 2002)
(Fig. 3). H2O2 is not only a toxic oxidant, but it
is also an important cellular messenger, regu-
lating the expression of numerous genes.
Besides the similarities striking differences
between CO and NO exist. NO is a free radical
and it is the most reactive of physiological
gases (Piantadosi, 2002). The reaction of NO
with ROS can result in formation of numerous
potent intermediates. It is likely that NO tox-
icity, which is higher than that of CO and oc-
curs above 100 p.p.m., derives from its reac-
tion with superoxide to form peroxynitrite
(Piantadosi, 2002). Accordingly, the potential
therapeutic doses of inhaled NO are probably
lower (65 p.p.m.) than of carbon monoxide
(500–1000 p.p.m.) (Thiemermann, 2001).
In vivo CO is almost immediately toxic at the
concentration of 0.4% (4000 p.p.m.) or more,
but the concentration of 0.01% (100 p.p.m.) is
tolerable and allowable for an exposure of sev-
eral hours (Otterbein & Choi, 2000). CO at low
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concentrations (10–500 p.p.m.) is well toler-
ated by cells, and the rodents can be exposed
to 500 p.p.m. continuously for up to 2 yr with-
out deleterious effects (Stupfel & Bouley,
1970; Otterbein & Choi, 2000).
The cellular effects of CO was studied basing
on the activity of HO-1 and the use of HO in-
hibitors, but data on cellular CO concentra-
tions are usually lacking. In contrast, exoge-
nous CO was applied at very different
amounts, sometimes very high. Such varied
modes of treatment may result in discrepant
results as will be discussed further.
REGULATION OF GENE EXPRESSION
IN HYPOXIA BY CO
In vascular smooth muscle cells (VSMC) cul-
tured under hypoxic conditions CO is pro-
duced as a result of induction of HO-1, and an
increase in cGMP content is observed (Morita
et al., 1995). The response is transient, with
cGMP peaking at 15 h and returning to base-
line by 48 h. It has been reported that very
high exogenous CO concentrations (5% or
more, even up to 80%) inhibited hypoxic in-
duction of erythropoietin (Huang et al., 1999),
vascular endothelial growth factor (VEGF)
(Goldberg & Schneider, 1994), endothelin-1
(ET-1) and platelet-derived growth factor
(PDGF) genes (Morita & Kourembanas,
1995). Endogenous CO, derived from HO ac-
tivity in VSMC growing in co-culture with en-
dothelial cells, inhibited the hypoxic induction
of PDGF-B and ET-1 in endothelium (Morita &
Kourembanas, 1995). In a feedback response,
the decreased production of those mitogens
by endothelial cells resulted in slowing down
the proliferation of the co-cultured VSMC
(Morita et al., 1997).
The underlying mechanism is not known. It
was suggested that it can be due to the inhibi-
tion of cytochrome P450 (Wang, 1998). In-
deed, cytochrome P450-linked monooxyge-
nase is responsible for the generation of vaso-
constricting substances, such as certain
arachidonic acid metabolites or ET-1. CO is an
inhibitor of cytochrome P450 and the level of
cytochrome P450 is controlled by the avail-
ability of cellular heme, which can be de-
graded to CO and biliverdin (Wang, 1998). A
decreased formation of vasconstrictors in re-
sponse to CO would lead to vascular relax-
ation.
The complex effect of CO on gene expression
in hypoxia requires elucidation. It has been
hypothesized that CO inhibits the hypoxic in-
duction of genes encoding vasoconstrictors in
smooth muscle cells in the early hypoxic
phase (Kourembanas, 2002). During chronic
hypoxia, however, low CO may tilt the balance
toward increased production of growth fac-
tors and vasoconstrictors that promote ves-
sel-wall remodeling (Kourembanas, 2002).
The main molecular sensor of the level of O2
in the cell is the transcription factor HIF-1 (for
a review see: Semenza, 2002). In the func-
tional state it is a heterodimer consisting of
two subunits, HIF-1 and HIF-1. This
heterodimer binds to a recognition site (HRE
— hypoxia response element) present in the
promoter of many genes regulated by
hypoxia, such as erythropoietin, VEGF, HO-1
or inducible nitric oxide synthase (iNOS) (for
a review see: Semenza, 2002).
HIF-1 subunits are constitutively produced
in the majority of cells, but dimer formation is
prevented by oxygen-dependent degradation
of HIF-1. Degradation occurs after hydroxy-
lation of specific proline residues (P402 and
P564) in the HIF-1 protein (for a review see:
Maxwell & Ratcliffe, 2002). At normal oxygen
tension the hydroxylation is performed by a
prolyl hydroxylase, which requires iron, O2
and 2-oxoglutarate as cofactors.
The data on the effect of CO on HIF-1 pro-
duction and activity are scarce and inconclu-
sive. It has been suggested that the cellular
hypoxia sensor is a heme-containing protein
(Goldberg & Schneider, 1994; Huang et al.,
1999) because cobalt chloride or iron
chelators can mimic the effects of hypoxia. It
has been hypothesized that in the presence of
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O2 that putative protein can bind O2 at a
heme site attaining a “relaxed” configura-
tion, whereas the absence of O2 confers a
“tense” conformation (cited after Kour-
embanas, 2002). It was claimed that CO, a
molecule known to interact with heme
groups, can inhibit the hypoxic induction of
genes by behaving similarly to O2 and shift-
ing the heme-protein to the relaxed configu-
ration (Kourembanas, 2002). However, the
recent discovery of the prolyl hydroxylase
which requires iron but is not a heme protein
sheds some doubts on this attractive hypoth-
esis.
Recently, a first eukaryotic transcription fac-
tor selectively affected by CO was discovered.
Dioum et al. (2002) have demonstrated that
binding of NPAS2, a member of the same fam-
ily of proteins to which HIF-1 belongs, is in-
hibited by CO, but is not influenced by NO nor
O2. NPAS2 is a homologue of CLOCK, a tran-
scription factor involved in modulation of cir-
cadian activity in the suprachiasmatic nucleus
(Rutter et al., 2002). NPAS2 is also present in
cells outside the central nervous system
(Dioum et al., 2002; Rutter et al., 2002), and,
interestingly, binds to a very similar DNA se-
quence (CACGTG) as HIF-1 (TACGTG). The
relationship and potential reciprocal influ-
ence of NPAS2 and HIF-1 on their activity is
not known and opens a new fascinating area
for further investigations.
The binding of the HIF-1 protein to HRE, as
determined by gel shift assay, was attenuated
in cells treated with exogenous CO in hypoxia
(Liu et al., 1998). However, the amount of
HIF-1 protein seemed not to be influenced at
5% CO concentration (Liu et al., 1998), while it
was decreased at high, 80% exposure (Huang
et al., 1999). How this relates to the physiolog-
ical situation is not known as the concentra-
tions of CO used in those experiments were
extremely high.
Interestingly, and in contrast to the studies
discussed above, our recent data indicate that
CO can be a positive regulator of VEGF syn-
thesis. We observed a significant induction of
VEGF in vascular smooth muscle cells cul-
tured in the presence of 1% CO (10000 p.p.m.)
in otherwise normoxic conditions (Dulak et
al., 2002; Dulak & Józkowicz, 2003). It ap-
pears that CO can modulate VEGF synthesis
also in other cell types. Accordingly, we ob-
served an increase in VEGF synthesis in
microvascular endothelial cells (HMEC-1)
treated with ruthenium carbonyl compound, a
representative of a new class of substances
named carbon monoxide releasing molecules
(CO-RM) (Jozkowicz et al., in press). Those
chemicals can release CO, and thus are equiv-
alent to the widely used NO donors
(Motterlini et al., 2002). Additionally, in
HMEC-1 the expression of VEGF was more
potently increased by 15d-PGJ2, a strong acti-
vator of HO-1, which induces the generation
of higher amount of CO than that attained af-
ter CO-RM treatment (Jozkowicz et al., in
press).
THE EFFECT OF CO ON
INFLAMMATORY REACTION
Great attention has been recently paid to
the presumed anti-inflammatory functions of
CO. It has been demonstrated that CO at a
physiological concentration (100–500
p.p.m.) inhibits the production of pro-inflam-
matory cytokines (Otterbein et al., 2000). In
macrophages treated with LPS the synthesis
of TNF, MIF and IL-1 is a marker of the in-
flammatory processes. When such cells were
kept in the presence of CO, the production of
those pro-inflammatory molecules de-
creased. Interestingly, CO upregulated the
synthesis of the anti-inflammatory cytokine
IL-10 (Otterbein et al., 2000). Looking fur-
ther for the mechanisms governing this po-
tentially preventive CO activity Otterbein et
al. (2000) found that CO action is independ-
ent of cGMP, but rather p38 kinase is neces-
sary (Fig. 3). Accordingly, CO failed to in-
hibit cytokine production in cells derived
from animals with targeted mutation in the
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MKK3 gene encoding a kinase activating p38
(Otterbein et al., 2000).
Interestingly, a positive loop may operate in
the anti-inflammatory functions of HO-1. As
mentioned, CO induces IL-10 synthesis in
monocytes, indicating for a role of HO-1. Re-
cently Lee & Chau (2002) have demonstrated
that IL-10 induces HO-1 expression, utilizing
CO as a mediator of anti-inflammatory activi-
ties.
The anti-inflammatory activity of CO may
underlie the protective effect of HO in such
processes like graft rejection (Ke et al., 2001;
2002; Sato et al., 2001) or development of ath-
erosclerosis (Ishikawa & Maruyama, 2001;
Ishikawa et al., 2001). It has been elegantly
demonstrated that HO activity is necessary
for inhibition of xenograft or allograft rejec-
tion. When hearts are transplanted from mice
to rats, the acute rejection can be prevented
by ablation of the complement system and
suppression immune response in the recipi-
ents by cobra venom factor treatment and
cyclosporine delivery (Soares et al., 1998).
However, when HO activity was additionally
blocked by HO inhibitors the grafts were re-
jected (Soares et al., 1998).
Through the influence on inflammatory re-
actions HO-1 overexpression may also pre-
vent the development of atherosclerosis (Shi
et al., 2000). The beneficial effect of HO-1 can
be exerted by CO-dependent inhibition of ves-
sel constriction (Suematsu et al., 1995), while
bilirubin can attenuate the adhesiveness of
leukocytes to the vessel wall (Duckers et al.,
2001; Hayashi et al., 1999; Kozma et al., 1997;
1999; Zhang et al., 2001). Additionally, HO-1
activity may modulate the inflammatory pro-
cesses by augmenting iron extrusion from the
cells of the blood vessel wall (Juan et al.,
2001).
Disruption of the HO-1 gene provides very
interesting data supporting the anti-inflam-
matory role of HO products. The life of HO-1
knockout mice is strongly affected by progres-
sive chronic inflammation characterized by
hepatosplenomegaly, lymphadenopathy and
leukocytosis. Animals are debilitated and die
at a young age from massive iron overload in
the liver and kidneys (Poss & Tonegawa,
1997a; 1997b). In response to chronic
hypoxia, they exhibit enhanced lipid pero-
xidation, accentuated oxidative damages, and
increased right ventricular infarcts with orga-
nized mural thrombi. Exposure to endotoxin
results in strong hepatocellular necrosis and
high mortality from endotoxic shock. The cells
derived from HO-1 targeted mice are highly
susceptible to heme- and hydrogen perox-
ide-mediated toxicity. HO-1 knockout mice are
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Figure 3. The effect of
CO on gene expression
and physiological func-
tions in the cardiovascu-
lar system.
In this figure only the po-
tential beneficial effects of
CO are mentioned. How-
ever, it remains to be estab-
lished whether the detri-
mental effects, which can
occur when HO-1 activity is
very high (Suttner &
Dennery, 1999), are solely
due to the increased re-
lease of free iron or are
also dependent on CO.
also more sensitive to pulmonary ischemia
compared to wild type counterparts (Fujita et
al., 2001). This could be prevented by inhala-
tion of CO (0.1%), which inhibited the hypoxic
induction of plasminogen activator inhibitor
(PAI-1), resulting in higher activity of tissue
plasminogen activator (tPA) and decreased fi-
brin deposition and lung inflammation (Fujita
et al., 2001).
Interestingly, the first case of human HO-1
deficiency was described after initial studies
on HO-1 targeted mice. The human case of
HO-1 deficiency exhibited similar features, in-
cluding iron deposition in renal and hepatic
tissues (Kawashima et al., 2002; Ohta et al.,
2000; Yachie et al., 1999). Lack of HO-1 activ-
ity resulted in extreme vulnerability of vessels
to common stressful stimuli, including infec-
tions and environmental toxic substances. A
cascade of inflammatory reactions and sus-
tained oxidative stress led to severe and per-
sistent vascular endothelial damage and de-
tachment. Cell lines derived from this patient
were strongly sensitive to hemin-induced in-
jury (Jeney et al., 2002). Importantly, HO-2,
which was expressed normally, did not pro-
vide efficient defense. These clinical symp-
toms demonstrate the critical importance of
HO-1 rather than HO-2 in iron metabolism
and in protection of vessels against oxidative
stress.
THE INHIBITORY EFFECT OF CO ON
CELL PROLIFERATION AND
APOPTOSIS
Growth factors, such as PDGF-BB (Durante
et al., 1999) or transforming growth factor 
(TGF- Kutty et al., 1994 Hill-Kapturczak et
al., 2000) which induce VSMC proliferation,
enhance also HO-1 expression. It has been hy-
pothesized that induction of HO-1 expression
represents a counterbalanced autocrine mech-
anisms which limits the SMC proliferation
(Kourembanas, 2002). Indeed, gene transfer
of HO-1 (Duckers et al., 2001; Liu et al., 2002;
Peyton et al., 2002; Zhang et al., 2002) or deliv-
ery of CO (Morita et al., 1997) blocked SMC
proliferation. Accordingly, inhibition of HO-1
activity potentiates SMC growth (Peyton et
al., 2002; Togane et al., 2000). The same effect
was obtained by treatment of growing SMC
with hemoglobin, a CO scavenger (Peyton et
al., 2002).
The effect of CO on the proliferation of
VSMC can be mediated by influence on tran-
scription factors. Among them E2F is a fam-
ily of cell-cycle specific transcription factors,
which regulate the expression of many genes
involved in cell proliferation, and govern the
transition of cells from the G1 to S phase. It
has been demonstrated that E2F is affected
by CO in a cGMP-dependent manner (Du-
rante, 2002). The involvement of cGMP in
the inhibition of VSMC proliferation was
also corroborated by experiments with YC-1,
which augments CO-dependent activation of
guanylate cyclase (Friebe & Koesling, 1998).
Accordingly, YC-1 attenuated the growth of
smooth muscle cells (Durante, 2002). More-
over, inhibition of guanylate cyclase with
methylene blue or ODQ ([1,2,4]-oxadiazolo-
[4,3-] quinoxaline-1-one) prevented CO ef-
fect on SMC cell cycle progression (Morita et
al., 1997).
The inhibition of the growth of VSMC can
have important consequences for prevention
of the vessel narrowing after balloon angio-
plasty, a therapeutic treatment applied to pa-
tients with atherosclerosis developing in their
coronary peripheral vessels. It is presumed
that quick regeneration of endothelial cells af-
ter angioplasty can inhibit restenosis due to
the restoration of endogenous modulatory
mechanisms governing vessel functions (for
review see: Dulak & Józkowicz, 2002). Inter-
estingly, it has been recently demonstrated
that CO protects endothelial cells from
apoptosis induced by various stimuli (Brouard
et al., 2000). This effect requires the activation
of the NF-B transcription factor and is de-
pendent on p38 kinase activity (Brouard et al.,
2002) indicating for a common mechanism of
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the protective action of CO in endotoxin- or
cytokine-induced inflammation and in regen-
erative processes after mechanical injury.
Of particular interest are observations dem-
onstrating that CO (or HO-1 transfection) en-
hanced proliferation of endothelial cells (Li
Volti et al., 2002; Malaguarnera et al., 2002;
Deramaudt et al., 1999). Thus, CO may behave
similarly like NO, which prevents the
apoptosis of endothelial cells and stimulates
their proliferation, but which inhibits the
growth of SMC (Kibbe et al., 2000; Tzeng et
al., 1997). The mechanisms of such effects of
those gases on endothelial cells are not
known. It can be speculated that both CO and
NO enhance the expression of VEGF, a
mitogen and anti-apoptotic factor for endothe-
lial cells (Dulak, 2001; Dulak et al., 2002;
Jozkowicz et al., in press). However, as endo-
thelial cells do not always produce detectable
quantities of VEGF, other mechanisms may
lay behind the effect of CO in endothelial cells.
Again, contradictory data have been also ob-
tained concerning the effect of CO on viability
of endothelial and vascular smooth muscle
cells. Thom et al. (2000) showed that main-
taining of bovine pulmonary artery endothe-
lial cells in the presence of 100 p.p.m. CO for
more than 1 h caused cell death, which could
be prevented by a caspase-1 inhibitor. The ef-
fect of CO was mediated by NO, as it was
blocked by an NO synthase inhibitor,
S-isopropylisothiourea, and the peroxynitrite
scavenger selenomethionine. Interestingly,
prior exposure of endothelial cells to a lower
concentration of CO, 10 p.p.m., conferred re-
sistance against the lethal effects of 100
p.p.m. CO, suggesting that the anti- and
pro-apoptoic effect of CO is concentration de-
pendent (Thom et al., 2000).
CONCLUSIONS
There is no doubt that CO exerts significant
effects on many pathways of the cellular me-
tabolism. In cells of the cardiovascular system
CO inhibits inflammatory response, influenc-
ing synthesis of cytokines, cell proliferation
and preventing cell apoptosis (Fig. 3). Those
effects are mediated through both cGMP-de-
pendent and cGMP-independent ways. The
physiological activity of CO may result in inhi-
bition of inflammatory reactions in hyper-
oxia, ischemia/reperfusion injury, atheroscle-
rosis and graft rejection.
It cannot be longer taken as a dogma that CO
is only a deadly substance with no physiologi-
cal functions. Rather, CO can be regarded as a
signaling molecule involved in, and maybe
even critical for many aspects of cellular me-
tabolism. Apparently, like in the case of the
majority of substances, its potentially harmful
or beneficial effects are dependent on the con-
centration. Regarding the physiological role,
low concentration of CO, equivalent to the
amount released by local activity of heme
oxygenase, can influence underlying pro-
cesses, inhibiting the inflammatory reactions.
However, the range of HO activity is much
broader, as it concomitantly releases bi-
liverdin and iron. The final outcome of HO ac-
tivity is thus probably different than the effect
expected from the action of separately deliv-
ered CO. The beneficial, and possibly thera-
peutic window of HO-1 appears to be quite
narrow, with protective effects exerted at
moderately increased activity, and harmful in-
fluences prevailing when iron release from de-
graded heme is very high (Dennery et al.,
2003; Suttner & Dennery, 1999). Therefore,
the potential beneficial and even therapeutic
effects ascribed to increased HO-1 expression
or CO supplementation have to be carefully re-
considered regarding the hypothetical risk of
aggravation of the oxidative stress due to the
increased CO and free iron release.
Although the complexity of the mechanisms
underlying CO actions on gene expression is
not well known, the results obtained in the
last few years have demonstrated its impor-
tance in modulation of inflammatory reaction
and cellular growth. They shed light on many
unknown aspects of CO functions and suggest
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new avenues for further investigations and
presumably therapeutic applications.
We are grateful to Professor Aleksander Koj
for his comments.
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